Integra LifeSciences Announces Contract with Premier, Inc.

Company Logo

PLAINSBORO, N.J., June 12, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq:IART) today announced that its Orthopedics and Tissue Technologies group signed a three-year group purchasing contract with Premier, Inc., a leading healthcare improvement company. The agreement will offer small bone orthopedic implants to Premier alliance members.

Integra is a leader in the development of small bone devices and instrumentation used to treat common degenerative conditions impacting the upper and lower extremities. The new contract allows Integra to meet Premier's needs in this area, and expands a rich Enterprise relationship while delivering broader access to its full portfolio, benefitting Premier alliance member healthcare organizations and their patients.

"I'm confident this newly established partnership will allow us to build a strong and lasting relationship with Premier," said Mark Augusti, Corporate Vice President and President, Integra Orthopedics and Tissue Technologies. "This mutually beneficial agreement marks a significant opportunity for both our organizations, and reflects our commitment to provide Premier members with the highest quality products and service for upper and lower extremity patients."

Integra's small bone implants are used to treat common degenerative conditions of the foot and hand resulting from arthritis and diabetes, at more than 5,200 hospitals and surgery centers in the United States. This agreement is a first step in Integra's Enterprise Selling efforts to develop larger enterprise agreements to support the company's future growth plans over the next five years, and represents the Company's first agreement of this type.

The new agreement has the potential to contribute significantly to the growth of Integra's Extremities business in 2015 and beyond, but the Company does not expect this contract to have a significant impact on 2014 financial results.

About Integra LifeSciences

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit

About Premier, Inc.

Premier, Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,000 U.S. hospitals and 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier's news and investor sites on; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, Foursquare and Premier's blog for more information about the company.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2013 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences: Media Gianna Sabella 609-936-2389 Investors Angela Steinway 609-936-2268

Source:Integra LifeSciences Holdings Corp.